Study Shows Distal Renal Tubular Acidosis Patient Outcomes Vary Across Country Lines

What is Distal Renal Tubular Acidosis? Distal renal tubular acidosis (dRTA) is a rare condition which affects approximately 1 in every 100,000 people worldwide. It is caused by a build up…

Continue Reading Study Shows Distal Renal Tubular Acidosis Patient Outcomes Vary Across Country Lines

Interim Data for Phase 3 Graft-versus-Host Disease Trial Looks Promising

According to a story from PR Newswire, the specialty pharmaceutical company Mallinckrodt plc recently announced the release of interim data from the company's Phase 3 clinical trial. This trial is…

Continue Reading Interim Data for Phase 3 Graft-versus-Host Disease Trial Looks Promising

Patient Advocate Foundation Provides Co-Pay Relief for Rare Disease Patients

What is the Patient Advocate Foundation? The Patient Advocate Foundation (PAF) is a non-profit, formed in 1994 that has one primary aim- eliminate the barriers to treatment too many patients…

Continue Reading Patient Advocate Foundation Provides Co-Pay Relief for Rare Disease Patients

New Device Could Help Langerhans Cell Histiocytosis Patients Monitor Their Own Chemotherapy Treatments

Langerhans Cell Histiocystosis Langerhans Cell Histiocytosis (LCH) Is a rare form of cancer caused by an excessive amount of Langerhan cells in the body. These cells form granulomas which can have a…

Continue Reading New Device Could Help Langerhans Cell Histiocytosis Patients Monitor Their Own Chemotherapy Treatments
Experimental Treatment Earns Breakthrough Therapy Designation for TK2 Deficiency, a Form of Mitochondrial Disease
argzombies / Pixabay

Experimental Treatment Earns Breakthrough Therapy Designation for TK2 Deficiency, a Form of Mitochondrial Disease

According to a story from BioSpace, the biopharmaceutical company Modis Therapeutics recently announced that the US Food and Drug Administration (FDA) has granted Breakthough Therapy designation for the company's experimental…

Continue Reading Experimental Treatment Earns Breakthrough Therapy Designation for TK2 Deficiency, a Form of Mitochondrial Disease
67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy
source: pixabay.com

67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy

  A grandmother of four in Maryland has recently become the first cancer patient to complete the experimental CAR-T cell procedure at Georgetown University Hospital. Daisy Diggs 67, who was…

Continue Reading 67 Year Old Non-Hodgkin’s Lymphoma Patient Given Second Chance at Life After Experimental Cell Therapy

Experimental Treatment for Macular Telangiectasia Type 2 Earns Fast Track Designation

According to a story from prnewswire.com, the biopharmaceutical company Neurotech Pharmaceuticals recently announced that the company had earned Fast Track designation from the US Food and Drug Administration (FDA). This…

Continue Reading Experimental Treatment for Macular Telangiectasia Type 2 Earns Fast Track Designation

Phase 3 Study in Europe Shows Continued Positive Results for Potential New Cystic Fibrosis Treatment

Cystic Fibrosis Cystic fibrosis (CF) is a rare disease caused by the lack (or malfunctioning) of the cystic fibrosis transmembrane conductance regulator (CTFR) protein. This occurs when children inherit a mutated…

Continue Reading Phase 3 Study in Europe Shows Continued Positive Results for Potential New Cystic Fibrosis Treatment